Abstract
In June 1999, the Association of British Neurologists (ABN) first published guidelines for the use of the licensed multiple sclerosis (MS) disease-modifying treatments (at that time β-interferon and glatiramer acetate)....
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have